Arrowhead Pharmaceuticals (ARWR) Long-Term Investments (2010 - 2023)

Arrowhead Pharmaceuticals' Long-Term Investments history runs 12 years deep, the most recent figure standing at $42.8 million for Q2 2023.

• Quarterly Long-Term Investments fell 74.2% year-over-year to $42.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $42.8 million (down 74.2% YoY) and the FY2022 annual result came in at $105.9 million, down 56.89% from the prior year.
• Long-Term Investments was $42.8 million for Q2 2023 at Arrowhead Pharmaceuticals, down from $78.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $245.6 million in Q3 2021 and bottomed at $26.3 million in Q4 2019.
• A 5-year average of $122.9 million and a median of $113.3 million in 2020 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments soared 321.04% — and 2023, when it tumbled 74.2%.
• Arrowhead Pharmaceuticals' Long-Term Investments stood at $26.3 million in 2019, then surged by 321.04% to $110.9 million in 2020, then soared by 96.27% to $217.6 million in 2021, then tumbled by 46.78% to $115.8 million in 2022, then slumped by 63.04% to $42.8 million in 2023.
• Business Quant data shows ARWR's Long-Term Investments at $42.8 million in Q2 2023, $78.8 million in Q1 2023, and $115.8 million in Q4 2022.